Extracorporeal photopheresis (ECP)
Evidence level: registry descriptions only; no efficacy source read
A procedure described in registry entries as used for CLAD and BOS and studied in registered trials; no efficacy source was read.
As of . Primary source: ClinicalTrials.gov NCT02181257.
Summary
The ClinicalTrials.gov entry NCT02181257 (Washington University School of Medicine) describes a phase 3 study of ECP in patients with refractory or newly diagnosed bronchiolitis obliterans syndrome after lung transplantation, run under a Medicare Coverage with Evidence Development decision, with 280 participants enrolled as listed. The entry NCT07434869 states that doctors often treat CLAD with ECP, that it can take up to six months to know whether the treatment is working, and that the study seeks early biomarkers of response. This record rests on those two registry descriptions only. No published efficacy study of ECP was read, so no statement about benefit or safety is made. It gives no dosing and no advice.
Details
- interventionType
- procedure (combination product)
Sources and links
Related
Links from this record
- studied in: Bronchiolitis obliterans syndrome (BOS)
Linked from (derived)
- tests: Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts
- studies biomarkers of response to: Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD
- reviews: Lymphocyte Depleting and Modulating Therapies for Chronic Lung Allograft Dysfunction
- assesses: European society for organ transplantation clinical practice guideline on prevention and treatment of chronic lung allograft dysfunction
- reports use of: Chronic lung allograft dysfunction after lung transplantation: prevention, diagnosis and treatment in 44 European centres
- models: Early Economic Model of Extracorporeal Photopheresis and Other Treatments of Chronic Lung Allograft Dysfunction After Lung Transplantation
- discusses: Global approaches to chronic lung allograft dysfunction: Toward evidence-based harmonization
- affects: No therapy of proven benefit for established CLAD
- affects: CLAD care and measurement vary between centres
Known gaps in this record
- published studies of ECP in CLAD or BOS: not read
- efficacy and safety: not assessed
- guideline statements on ECP: not read
- dosing and schedule: deliberately not recorded
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.